Please assess the completion status of the following clinical trial:

Trial Title: Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men/women \> 18 years of age~* curative resection/ileocolonic anastomosis for Crohn's disease~* may have received previously received infliximab~* if on oral aminosalicylates or corticosteroids, dose must be stable for 4 weeks prior to surgery~* if on 6-mercaptopurine,azathioprine or methotrexate,individual must have been on it for minimum of 3 months prior to surgery with stable dose for 4 weeks~* men and women must use adequate birth control for duration of study and for 6 months after receiving the last infusion~* antibiotics for treatment of Crohn's disease must be discontinued within 12 weeks after surgery; antibiotics are allowable throughout study as long as primary purpose of antibiotic therapy is not for primary treatment of Crohn's disease~* screening lab results must meet screening criteria (hemoglobin = or \> 8.5g/dL; Serum glutamic oxaloacetic transaminase ,3 times upper normal limit,platelets =or\> 100 x 10 9th/L; lymphocytes count =or\> 0.5 x 10 9th/L and neutrophils =or\> 1.0 x 10 9th/L~* have a documented negative reaction to a purified protein derivative skin test performed within 3 months prior to baseline~* have a normal chest radiograph results within 3 months prior to baseline~* are capable of providing written informed consent and obtained prior to conducting any protocol-specified procedures~* willing to adhere to the study visit schedule and other protocol requirements~* are considered eligible according to the tuberculosis eligibility assessment, screening and early detection of reactivation rules~* patients who undergo resective surgery and primary ileocolonic anastomosis with a temporary ileostomy upon takedown of the diverting ileostomy.~Exclusion Criteria:~* patients with greater than 10 years of Crohn's disease requiring first resection of a short (\<10cm) fibrostenotic stricture~* macroscopically active disease at anastomosis at time of surgery~* presence of stoma~* prior severe infusion reaction to infliximab~* history of anaphylaxis to murine products or other chimeric proteins~* any of the following medications taken within 12 weeks of surgery: cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, investigational drugs, or medications targeted at reducing tumor necrosis factor~* have a positive stool culture for enteric pathogens, pathogenic ova or parasites, or Clostridium difficile toxin and have clinically significant signs of an enteric infection at screening~* women who are pregnant, nursing or planning pregnancy during the trial or within 6 months after the last infusion~* patient with active tuberculosis, patient newly diagnosed with latent tuberculosis who's receiving tuberculosis prophylaxis, patient with recent close contact to individual with active tuberculosis~* have or have had opportunistic infection within 6 months of screening~* have chest radiograph within 3 months prior to screening that shows malignancy, infection, or abnormalities suggestive of tuberculosis~* documentation of seropositive for HIV~* documentation of a positive test for hepatitis B surface antigen or a history of documented hepatitis C~* have current signs/symptoms of systemic lupus erythematosus, or severe progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral diseases~* presence of a transplanted solid organ (with exception of corneal transplant \> 3 months prior to randomization)~* Have any current or known malignancy or have history of malignancy within 5 years of screening(except for squamous or basal cell carcinoma of the skin that has been fully excised with no evidence of recurrence)~* have history of lymphoproliferative disease or splenomegaly~* have known substance abuse(drug/alcohol)/dependency within the previous 3 years, history of noncompliance with medical regimens, or other condition that may interfere with adherence to protocol requirements~* are unwilling/unable to undergo multiple venipunctures because of poor tolerability or lack of easy access~* known history of demyelinating disease~* a chronic or recurrent infectious disease~* serious infection, hospitalization for infection, or treatment with IV antibiotics for infection within 2 months prior to randomization~* a serious concomitant illness that may interfere with participation in trial~* concomitant diagnosis/history of congestive heart failure~* current use of prescription doses or chronic/frequent use of non-steroidal anti-inflammatory drugs~* ulcerative colitis~* concurrent participation in another investigative trial~* use of any investigational drug within 30 days prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete